Advarra has announced the formation of the Council for Responsible Use of AI in Clinical Trials.

Advarra 宣布成立临床试验中负责任使用人工智能的理事会。

This initiative aims to foster collaboration within the life sciences sector, focusing on the responsible integration of artificial intelligence (AI) into clinical trial operations.

该倡议旨在促进生命科学领域的合作，重点关注将人工智能 (AI) 负责任地整合到临床试验操作中。

The newly established Council includes representatives from key life sciences organisations such as Sanofi, Recursion, and Velocity Clinical Research. These founding members bring a wide range of expertise in AI and machine learning, regulatory science, data strategy, and clinical development. The Council will act as a platform for sharing insights, setting standards, and addressing critical challenges surrounding the application of AI in clinical research..

新成立的理事会包括来自赛诺菲、Recursion 和 Velocity Clinical Research 等关键生命科学组织的代表。这些创始成员在人工智能和机器学习、监管科学、数据战略以及临床开发方面带来了广泛的专业知识。该理事会将作为分享见解、制定标准和应对临床研究中人工智能应用相关的关键挑战的平台。

Advarra’s role as a central player in the clinical research ecosystem, with its comprehensive understanding of study processes and stakeholder challenges, places it in a unique position to guide this industry-wide effort.

Advarra作为临床研究生态系统中的重要参与者，凭借其对研究流程和利益相关者挑战的全面理解，处于引导这一全行业努力的独特位置。

The Council is focused on accelerating the responsible use of AI across all stages of the clinical trial lifecycle. Key areas of work will include:

该委员会专注于加速在临床试验生命周期的所有阶段中负责任地使用人工智能。重点工作领域将包括：

This approach is designed to align with the latest regulatory considerations, including recent draft guidance from the US FDA, which highlights the need for clarity and accountability in AI applications.

这种方法旨在符合最新的监管要求，包括美国FDA最近的草案指南，该指南强调了人工智能应用中对清晰性和问责性的需求。

As the use of AI becomes more common in clinical development, there is growing interest in using real-world and operational data to improve trial efficiency and accuracy. The Council aims to translate theoretical advancements into real-world best practices by focusing on protocol amendments, participant recruitment, data handling, and decision-making processes..

随着人工智能在临床开发中的应用日益普遍，利用真实世界数据和操作数据来提高试验效率和准确性的兴趣也在增长。该委员会旨在通过关注方案修订、参与者招募、数据处理和决策过程，将理论进展转化为现实世界中的最佳实践。

This initiative recognises that progress in AI must go hand-in-hand with clear governance, shared responsibility, and stakeholder alignment to truly benefit trial participants, sponsors, sites, and the wider research community.

这项倡议认识到，人工智能的进步必须与明确的治理、共同的责任和利益相关者的协调齐头并进，才能真正造福试验参与者、赞助者、站点以及更广泛的研究社区。

To support its goals, the Council will share its work through white papers, peer-reviewed publications, webinars, and conference presentations. It also plans to host industry roundtables and engage with regulatory bodies and standards organisations to gather feedback and ensure its recommendations are broadly relevant and forward-looking..

为了实现其目标，该委员会将通过白皮书、同行评审出版物、网络研讨会和会议演讲分享其工作。它还计划举办行业圆桌会议，并与监管机构和标准组织接触，以收集反馈并确保其建议具有广泛的适用性和前瞻性。

Through this collaborative model, the Council aims to guide the responsible use of AI in clinical trials and contribute to improving outcomes across the healthcare and life sciences landscape.

通过这种协作模式，该委员会旨在指导临床试验中人工智能的负责任使用，并有助于改善整个医疗保健和生命科学领域的发展成果。

Source: prnewswire.com

来源：prnewswire.com